LU91056I2 - Dérivés de 1-biphénylimidazole, leur préparation et leur utilisation thérapeutique. - Google Patents
Dérivés de 1-biphénylimidazole, leur préparation et leur utilisation thérapeutique.Info
- Publication number
- LU91056I2 LU91056I2 LU91056C LU91056C LU91056I2 LU 91056 I2 LU91056 I2 LU 91056I2 LU 91056 C LU91056 C LU 91056C LU 91056 C LU91056 C LU 91056C LU 91056 I2 LU91056 I2 LU 91056I2
- Authority
- LU
- Luxembourg
- Prior art keywords
- alkyl
- aryl
- alkoxy
- substd
- halo
- Prior art date
Links
- 230000001225 therapeutic effect Effects 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 abstract 9
- 125000003118 aryl group Chemical group 0.000 abstract 8
- 125000003545 alkoxy group Chemical group 0.000 abstract 6
- 125000001475 halogen functional group Chemical group 0.000 abstract 6
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 5
- 125000004453 alkoxycarbonyl group Chemical group 0.000 abstract 4
- 125000004849 alkoxymethyl group Chemical group 0.000 abstract 3
- 125000003342 alkenyl group Chemical group 0.000 abstract 2
- 125000005129 aryl carbonyl group Chemical group 0.000 abstract 2
- 125000001589 carboacyl group Chemical group 0.000 abstract 2
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 2
- -1 pivaloyloxymethyl Chemical group 0.000 abstract 2
- 125000006569 (C5-C6) heterocyclic group Chemical group 0.000 abstract 1
- YYYXAGYRXXVILU-UHFFFAOYSA-N 2-benzyl-1-phenylimidazole Chemical compound C=1C=CC=CC=1CC1=NC=CN1C1=CC=CC=C1 YYYXAGYRXXVILU-UHFFFAOYSA-N 0.000 abstract 1
- LXBGSDVWAMZHDD-UHFFFAOYSA-N 2-methyl-1h-imidazole Chemical compound CC1=NC=CN1 LXBGSDVWAMZHDD-UHFFFAOYSA-N 0.000 abstract 1
- 125000002252 acyl group Chemical group 0.000 abstract 1
- 125000004442 acylamino group Chemical group 0.000 abstract 1
- 125000002947 alkylene group Chemical group 0.000 abstract 1
- 125000005530 alkylenedioxy group Chemical group 0.000 abstract 1
- MDFFNEOEWAXZRQ-UHFFFAOYSA-N aminyl Chemical compound [NH2] MDFFNEOEWAXZRQ-UHFFFAOYSA-N 0.000 abstract 1
- 150000002148 esters Chemical class 0.000 abstract 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 abstract 1
- XLSZMDLNRCVEIJ-UHFFFAOYSA-N methylimidazole Natural products CC1=CNC=N1 XLSZMDLNRCVEIJ-UHFFFAOYSA-N 0.000 abstract 1
- 125000003367 polycyclic group Chemical group 0.000 abstract 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 abstract 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 abstract 1
- 125000005958 tetrahydrothienyl group Chemical group 0.000 abstract 1
- 125000004632 tetrahydrothiopyranyl group Chemical group S1C(CCCC1)* 0.000 abstract 1
- 125000004299 tetrazol-5-yl group Chemical group [H]N1N=NC(*)=N1 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
- C07F7/1804—Compounds having Si-O-C linkages
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/582—Recycling of unreacted starting or intermediate materials
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Dental Preparations (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Phenolic Resins Or Amino Resins (AREA)
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2709891 | 1991-02-21 | ||
JP9658891 | 1991-04-26 | ||
JP13488991 | 1991-06-06 | ||
JP16713891 | 1991-07-08 | ||
JP17397291 | 1991-07-15 | ||
JP18484191 | 1991-07-24 |
Publications (1)
Publication Number | Publication Date |
---|---|
LU91056I2 true LU91056I2 (fr) | 2004-10-19 |
Family
ID=27549327
Family Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
LU91056C LU91056I2 (fr) | 1991-02-21 | 2004-01-26 | Dérivés de 1-biphénylimidazole, leur préparation et leur utilisation thérapeutique. |
LU91330C LU91330I2 (fr) | 1991-02-21 | 2007-04-02 | Une combinaison d'olmesartan medoxomil, optionnellement sous la forme d'un sel pharmaceutiquement acceptable et d'hydrochlorothiazide (olmetec plus) |
LU91571C LU91571I2 (fr) | 1991-02-21 | 2009-05-11 | Une combinaison de olmesartan medoxomil, facultativement sous forme d'un sel pharmaceutiquement acceptable, et d'un bésylate d'amplodipine |
LU91847C LU91847I2 (fr) | 1991-02-21 | 2011-07-26 | Combinaison de olmesartan medoxomil, optionnellement sous forme d'un sel pharmaceutiquement acceptable, et amlodipine besylate et hydrochlorothiazide |
Family Applications After (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
LU91330C LU91330I2 (fr) | 1991-02-21 | 2007-04-02 | Une combinaison d'olmesartan medoxomil, optionnellement sous la forme d'un sel pharmaceutiquement acceptable et d'hydrochlorothiazide (olmetec plus) |
LU91571C LU91571I2 (fr) | 1991-02-21 | 2009-05-11 | Une combinaison de olmesartan medoxomil, facultativement sous forme d'un sel pharmaceutiquement acceptable, et d'un bésylate d'amplodipine |
LU91847C LU91847I2 (fr) | 1991-02-21 | 2011-07-26 | Combinaison de olmesartan medoxomil, optionnellement sous forme d'un sel pharmaceutiquement acceptable, et amlodipine besylate et hydrochlorothiazide |
Country Status (23)
Country | Link |
---|---|
EP (2) | EP0503785B3 (fr) |
JP (1) | JPH07121918B2 (fr) |
KR (1) | KR0128289B1 (fr) |
CN (3) | CN1045770C (fr) |
AT (2) | ATE200777T1 (fr) |
CA (2) | CA2229000C (fr) |
CZ (1) | CZ289194B6 (fr) |
DE (6) | DE122005000051I1 (fr) |
DK (2) | DK0503785T3 (fr) |
ES (2) | ES2157895T7 (fr) |
FI (2) | FI112942B3 (fr) |
GR (2) | GR3035906T3 (fr) |
HK (2) | HK1011361A1 (fr) |
HU (3) | HU223338B1 (fr) |
IE (1) | IE920540A1 (fr) |
IL (3) | IL114996A (fr) |
IS (1) | IS1756B (fr) |
LU (4) | LU91056I2 (fr) |
NL (3) | NL300133I2 (fr) |
NO (6) | NO304516B3 (fr) |
NZ (1) | NZ241681A (fr) |
PT (2) | PT503785E (fr) |
RU (1) | RU2128173C1 (fr) |
Families Citing this family (103)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5616599A (en) * | 1991-02-21 | 1997-04-01 | Sankyo Company, Limited | Angiotensin II antagosist 1-biphenylmethylimidazole compounds and their therapeutic use |
ATE199548T1 (de) * | 1992-06-02 | 2001-03-15 | Sankyo Co | 4-carboxyimidazolderivate als angiotensin-ii- antagonisten und ihre therapeutische verwendung |
RU2109736C1 (ru) * | 1992-12-17 | 1998-04-27 | Санкио Компани Лимитед | Производные бифенила и способ их получения |
US5395844A (en) * | 1993-06-10 | 1995-03-07 | The Du Pont Merck Pharmaceutical Company | Imidazole 5-position substituted angiotensin II antagonists |
DK1110551T3 (da) * | 1994-03-16 | 2004-06-07 | Sankyo Co | Okulærtensionssænkende middel |
TW442301B (en) | 1995-06-07 | 2001-06-23 | Sanofi Synthelabo | Pharmaceutical compositions containing irbesartan |
AUPN786896A0 (en) | 1996-02-02 | 1996-02-29 | Telstra Corporation Limited | A network fault system |
KR100540618B1 (ko) | 1996-07-15 | 2006-01-12 | 상꾜 가부시키가이샤 | 의약 조성물 |
WO1998034922A1 (fr) * | 1997-02-05 | 1998-08-13 | Sankyo Company, Limited | Agent destine a la prophylaxie ou la therapie des complications diabetiques |
EP1193258A4 (fr) | 1999-06-22 | 2002-11-13 | Takeda Chemical Industries Ltd | Methode de preparation de derives d'imidazole |
SE9903028D0 (sv) | 1999-08-27 | 1999-08-27 | Astra Ab | New use |
PE20010781A1 (es) * | 1999-10-22 | 2001-08-08 | Takeda Chemical Industries Ltd | Compuestos 1-(1h-imidazol-4-il)-1-(naftil-2-sustituido)etanol, su produccion y utilizacion |
JP4521844B2 (ja) * | 2000-04-18 | 2010-08-11 | 日本曹達株式会社 | 4,5−ジシアノイミダゾールの製造方法 |
EP1314425A4 (fr) * | 2000-08-30 | 2004-06-02 | Sankyo Co | Compositions medicinales utilisees dans la prevention ou le traitement de l'insuffisance cardiaque |
US8168616B1 (en) | 2000-11-17 | 2012-05-01 | Novartis Ag | Combination comprising a renin inhibitor and an angiotensin receptor inhibitor for hypertension |
HUP0400553A3 (en) * | 2000-11-21 | 2010-03-29 | Daiichi Sankyo Company | Pharmaceutical compositions |
WO2003020315A1 (fr) * | 2001-08-28 | 2003-03-13 | Sankyo Company, Limited | Compositions medicinales contenant un antagoniste du recepteur d'angiotensine ii |
AU2004208615C1 (en) | 2003-01-31 | 2010-05-13 | Daiichi Sankyo Company, Limited | Medicine for prevention of and treatment for arteriosclerosis and hypertension |
CN1197866C (zh) * | 2003-03-21 | 2005-04-20 | 上海医药工业研究院 | 4,6-二氢呋喃并[3,4-d]咪唑-6-酮衍生物及其盐和制备方法 |
EP1614428A4 (fr) | 2003-04-15 | 2010-01-06 | Sankyo Co | Medicament destine a la prevention ou au traitement des maladies oculaires angiogeniques |
US7732162B2 (en) | 2003-05-05 | 2010-06-08 | Probiodrug Ag | Inhibitors of glutaminyl cyclase for treating neurodegenerative diseases |
GB0316546D0 (en) | 2003-07-15 | 2003-08-20 | Novartis Ag | Process for the manufacture of organic compounds |
EP2428516A1 (fr) | 2003-11-19 | 2012-03-14 | Metabasis Therapeutics, Inc. | Nouvelles substances thyromimetiques contenant du phosphore |
GB0327839D0 (en) | 2003-12-01 | 2003-12-31 | Novartis Ag | Organic compounds |
JP2005206603A (ja) * | 2004-01-21 | 2005-08-04 | Teva Pharmaceutical Industries Ltd | カンデサルタンシレキセチルの調製 |
GB0402262D0 (en) | 2004-02-02 | 2004-03-10 | Novartis Ag | Process for the manufacture of organic compounds |
EP1713795A2 (fr) | 2004-02-11 | 2006-10-25 | Teva Pharmaceutical Industries Ltd. | Polymorphes de candesartan cilexetil |
US7157584B2 (en) | 2004-02-25 | 2007-01-02 | Takeda Pharmaceutical Company Limited | Benzimidazole derivative and use thereof |
KR20070006774A (ko) | 2004-03-17 | 2007-01-11 | 노파르티스 아게 | 치료에서 레닌 억제제의 용도 |
CA2573800A1 (fr) * | 2004-09-02 | 2006-03-16 | Teva Pharmaceutical Industries Ltd. | Preparation d'olmesartan medoxomil |
CA2580862A1 (fr) | 2004-10-08 | 2006-04-20 | Novartis Ag | Utilisation d'inhibiteurs de renine pour la prevention ou le traitement du dysfonctionnement diastolique ou de la cardiopathie diastolique |
RU2007115900A (ru) | 2004-10-27 | 2008-11-10 | Дайити Санкио Компани, Лимитед (Jp) | Производные бензола, имеющие 2 или более заместителей |
WO2006073518A1 (fr) * | 2004-12-30 | 2006-07-13 | Teva Pharmaceutical Industries Ltd. | Procédé de synthèse d'olmesartan medoxomil à un ph supérieur à 2,5 |
US7563814B2 (en) * | 2005-01-03 | 2009-07-21 | Teva Pharmaceutical Industries Ltd. | Olmesartan medoxomil with reduced levels of impurities |
ES2334386T3 (es) * | 2005-04-22 | 2010-03-09 | Daiichi Sankyo Company, Limited | Producto farmaceutico para la prevencion o el tratamiento de una enfermedad metabolica osea. |
EP1910343B1 (fr) * | 2005-07-29 | 2014-10-29 | Krka | Procédé de préparation d'olmesartane medoxomil |
EP1816131A1 (fr) * | 2006-02-06 | 2007-08-08 | KRKA, tovarna zdravil, d.d., Novo mesto | Procédé pour la préparation du olmesartan medoxomil |
CZ299265B6 (cs) * | 2005-10-20 | 2008-05-28 | Zentiva, A. S. | Zpusob výroby 1-(cyklohexyloxykarbonyloxy)ethyl-2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)bifenyl-4-yl]methyl]benzimidazol-7-karboxylátu (candesartan cilexetilu) |
CZ299902B6 (cs) * | 2005-10-27 | 2008-12-29 | Zentiva, A. S | Zpusob odstranování trifenylmethanové chránicí skupiny u prekurzoru antihypertenzních léciv |
EP1801111B1 (fr) * | 2005-12-20 | 2014-07-16 | LEK Pharmaceuticals d.d. | Formes polymorphes du Olmesartan Medoxomil |
WO2007097451A1 (fr) | 2006-02-27 | 2007-08-30 | Takeda Pharmaceutical Company Limited | Emballage pharmaceutique |
EP1891952B1 (fr) | 2006-05-04 | 2011-10-05 | LEK Pharmaceuticals d.d. | Composition pharmaceutique d'olmésartan médoxomil |
WO2007148344A2 (fr) * | 2006-06-19 | 2007-12-27 | Matrix Laboratories Limited | Procédé de préparation d'olmésartan médoxomil |
EP1988091B1 (fr) | 2007-02-07 | 2015-06-10 | Kyowa Hakko Kirin Co., Ltd. | Composés tricycliques |
CN101668525A (zh) | 2007-03-01 | 2010-03-10 | 前体生物药物股份公司 | 谷氨酰胺酰环化酶抑制剂的新用途 |
JPWO2008117707A1 (ja) * | 2007-03-23 | 2010-07-15 | 第一三共株式会社 | オルメサルタンメドキソミルの粉砕結晶 |
EP2142514B1 (fr) | 2007-04-18 | 2014-12-24 | Probiodrug AG | Dérivés de thio-urée utilisés comme inhibiteurs de la glutaminyl cyclase |
TWI448284B (zh) * | 2007-04-24 | 2014-08-11 | Theravance Inc | 雙效抗高血壓劑 |
CN101311168B (zh) * | 2007-05-21 | 2010-12-08 | 上海医药工业研究院 | 4-(1-羟基-1-甲基乙基)-2-丙基咪唑-5-羧酸酯的制备方法 |
CN101311169B (zh) * | 2007-05-21 | 2011-03-16 | 上海医药工业研究院 | 4-(1-羟基-1-甲基乙基)-2-丙基咪唑-5-羧酸乙酯的制备方法 |
ES2393885T7 (es) | 2007-06-04 | 2014-01-30 | Synergy Pharmaceuticals Inc. | Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos |
US8969514B2 (en) | 2007-06-04 | 2015-03-03 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases |
GB0710680D0 (en) * | 2007-06-05 | 2007-07-11 | Generics Uk Ltd | Novel crystalline form of olmesartan medoxmil |
ES2446296T3 (es) * | 2007-06-22 | 2014-03-07 | Daiichi Sankyo Company, Limited | Agente medicinal para el tratamiento de trastornos de la circulación cerebral o del flujo sanguíneo cerebral inducidos por beta amiloide |
ES2522968T3 (es) | 2008-06-04 | 2014-11-19 | Synergy Pharmaceuticals Inc. | Agonistas de guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos |
WO2009151016A1 (fr) * | 2008-06-09 | 2009-12-17 | 第一三共株式会社 | Procédé de fabrication d’un composé de 1-biphénylméthylimidazole |
AU2009270833B2 (en) | 2008-07-16 | 2015-02-19 | Bausch Health Ireland Limited | Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders |
WO2010016549A1 (fr) | 2008-08-06 | 2010-02-11 | 協和発酵キリン株式会社 | Composé tricyclique |
JP5395908B2 (ja) | 2008-11-17 | 2014-01-22 | 浙江海正薬業股▲ふん▼有限公司 | 4−(1−ヒドロキシ−1−メチルエチル)−2−プロピルイミダゾール−5−カルボン酸エステルの製造方法 |
JP2009102340A (ja) * | 2008-12-04 | 2009-05-14 | Daiichi Sankyo Co Ltd | イミダゾール誘導体の製造法(2) |
WO2010093601A1 (fr) | 2009-02-10 | 2010-08-19 | Metabasis Therapeutics, Inc. | Nouveaux thyromimetiques contenant de l'acide sulfonique et methodes d'utilisation associees |
ES2753874T3 (es) | 2009-04-28 | 2020-04-14 | Daiichi Sankyo Co Ltd | Cristales de solvato novedosos |
CA2759163C (fr) | 2009-04-28 | 2015-02-17 | Daiichi Sankyo Company, Limited | Procede de production de l'olmesartan medoxomil |
SG178953A1 (en) | 2009-09-11 | 2012-04-27 | Probiodrug Ag | Heterocylcic derivatives as inhibitors of glutaminyl cyclase |
CN102050816A (zh) * | 2009-10-28 | 2011-05-11 | 北京万全阳光医学技术有限公司 | 一种合成奥美沙坦酯的方法 |
HUP0900788A2 (en) | 2009-12-16 | 2011-11-28 | Sanofi Aventis | Process for producing 4-bromomethyl-biphenyl derivatives |
WO2011083112A2 (fr) | 2010-01-05 | 2011-07-14 | Ratiopharm Gmbh | Forme posologique orale solide contenant de l'olmésartan médoxomil |
ES2586231T3 (es) | 2010-03-03 | 2016-10-13 | Probiodrug Ag | Inhibidores de glutaminil ciclasa |
DK2545047T3 (da) | 2010-03-10 | 2014-07-28 | Probiodrug Ag | Heterocycliske inhibitorer af glutaminylcyclase (QC, EC 2.3.2.5) |
WO2011131748A2 (fr) | 2010-04-21 | 2011-10-27 | Probiodrug Ag | Nouveaux inhibiteurs |
JP5137996B2 (ja) * | 2010-04-28 | 2013-02-06 | 日本曹達株式会社 | 4,5−ジシアノイミダゾールの製造方法 |
IT1400311B1 (it) | 2010-05-10 | 2013-05-24 | Menarini Int Operations Lu Sa | Associazione di inibitori della xantina ossidasi e antagonisti del recettore dell'angiotensina ii e loro uso. |
EP2425859A1 (fr) | 2010-08-08 | 2012-03-07 | Abdi Ibrahim Ilac Sanayi ve Ticaret Anonim Sirketi | Formulations de l'olmesartane |
US9616097B2 (en) | 2010-09-15 | 2017-04-11 | Synergy Pharmaceuticals, Inc. | Formulations of guanylate cyclase C agonists and methods of use |
CN102060778B (zh) * | 2010-12-24 | 2012-05-23 | 江苏江神药物化学有限公司 | 一种4-(1-羟基-1-甲基乙基)-2-丙基咪唑-5-羧酸乙酯的合成方法 |
CN102206208A (zh) * | 2010-12-24 | 2011-10-05 | 上海现代制药股份有限公司 | 含低水平杂质的奥美沙坦酯的制备方法 |
ES2570167T3 (es) | 2011-03-16 | 2016-05-17 | Probiodrug Ag | Derivados de benzimidazol como inhibidores de glutaminil ciclasa |
WO2013018899A1 (fr) | 2011-08-03 | 2013-02-07 | 協和発酵キリン株式会社 | Dérivé de dibenzooxépine |
AP2014007766A0 (en) | 2011-12-15 | 2014-07-31 | Takeda Pharmaceuticals Usa Inc | Combination os azilsartan and chlorthlidone for treating hypertension black patients |
CN103304550B (zh) * | 2012-03-16 | 2016-01-27 | 湖南欧亚生物有限公司 | 一种奥美沙坦酯的制备方法 |
CN104583185A (zh) | 2012-08-31 | 2015-04-29 | 株式会社Api | 联芳基化合物的制造方法 |
EP2902385B1 (fr) | 2012-09-26 | 2019-01-09 | API Corporation | Procédé de déprotection pour un composé tétrazole |
US9486503B2 (en) | 2012-10-04 | 2016-11-08 | Shionogi & Co., Ltd. | Medicinal agent for suppressing malignant tumor metastasis |
CN103012382B (zh) * | 2012-12-05 | 2016-10-05 | 迪沙药业集团有限公司 | 一种奥美沙坦酯的制备方法 |
CN103044407A (zh) * | 2012-12-20 | 2013-04-17 | 安徽悦康凯悦制药有限公司 | 奥美沙坦酯的制备方法 |
CN103965167A (zh) * | 2013-01-29 | 2014-08-06 | 通化济达医药有限公司 | 咪唑羧酸衍生物 |
JP2014152127A (ja) * | 2013-02-06 | 2014-08-25 | Tokuyama Corp | オルメサルタンメドキソミルの製造方法 |
JP2016514671A (ja) | 2013-03-15 | 2016-05-23 | シナジー ファーマシューティカルズ インコーポレイテッド | グアニル酸シクラーゼのアゴニストおよびその使用 |
CA2905435A1 (fr) | 2013-03-15 | 2014-09-25 | Synergy Pharmaceuticals Inc. | Compositions utiles pour le traitement de troubles gastro-intestinaux |
US10011637B2 (en) | 2013-06-05 | 2018-07-03 | Synergy Pharmaceuticals, Inc. | Ultra-pure agonists of guanylate cyclase C, method of making and using same |
ES2847904T3 (es) | 2013-07-23 | 2021-08-04 | Daiichi Sankyo Co Ltd | Medicamento para la prevención o el tratamiento de la hipertensión |
CN103880825B (zh) * | 2014-03-14 | 2019-03-05 | 浙江华海药业股份有限公司 | 一种高纯的三苯甲基奥美沙坦酯的制备工艺 |
CN104356069B (zh) * | 2014-11-18 | 2016-09-14 | 黄冈鲁班药业有限公司 | 奥美沙坦酯中间体4-(1-羟基-1-甲基乙基)-2-丙基咪唑-5-羧酸乙酯的制备方法及应用 |
CN104447564B (zh) * | 2014-11-24 | 2016-08-31 | 广州天赐高新材料股份有限公司 | 高纯度4,5-二氰基-2-三氟甲基咪唑及其盐的制备方法 |
CN104402873A (zh) * | 2014-12-02 | 2015-03-11 | 千辉药业(安徽)有限责任公司 | 一种奥美沙坦酯中间体的制备方法 |
CN105481842A (zh) * | 2015-12-15 | 2016-04-13 | 江苏中邦制药有限公司 | 一种奥美沙坦酯的制备方法 |
CA3015964C (fr) | 2016-03-24 | 2021-08-03 | Daiichi Sankyo Company, Limited | Medicament pour le traitement d'une maladie renale |
CN106749195A (zh) * | 2016-12-30 | 2017-05-31 | 青岛黄海制药有限责任公司 | 一种奥美沙坦酯中间体杂质合成、鉴定的方法 |
CN107474042A (zh) * | 2017-09-07 | 2017-12-15 | 浙江华海致诚药业有限公司 | 一种三苯甲基奥美沙坦酯的晶型h |
PL3461819T3 (pl) | 2017-09-29 | 2020-11-30 | Probiodrug Ag | Inhibitory cyklazy glutaminylowej |
CN109081812B (zh) * | 2018-08-30 | 2022-08-16 | 黄冈鲁班药业股份有限公司 | 4-(1-羟基-1-甲基乙基)-2-丙基咪唑-5-羧酸乙酯一水合物 |
KR102131359B1 (ko) | 2018-09-07 | 2020-07-07 | 오토텔릭바이오 주식회사 | 안정성이 향상된 의약 조성물 |
CN112778209B (zh) * | 2019-11-04 | 2024-05-14 | 宜昌东阳光长江药业股份有限公司 | 一种二酸的制备方法 |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5671074A (en) * | 1979-11-12 | 1981-06-13 | Takeda Chem Ind Ltd | 1,2-disubstituted-4-halogenoimidazole-5-acetic acid derivative |
JPS5671073A (en) | 1979-11-12 | 1981-06-13 | Takeda Chem Ind Ltd | Imidazole derivative |
IE802177L (en) | 1980-10-21 | 1981-05-12 | Takeda Chemical Industries Ltd | Imidazol-5-ylacetic acid derivatives |
US4812462A (en) | 1986-04-01 | 1989-03-14 | Warner-Lambert Company | 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-6-carboxylic acid analogs having antihypertensive activity |
CA1334092C (fr) * | 1986-07-11 | 1995-01-24 | David John Carini | Imidazoles bloquant les recepteurs de l'angiotensine ii |
US5015651A (en) * | 1988-01-07 | 1991-05-14 | E. I. Du Pont De Nemours And Company | Treatment of hypertension with 1,2,4-angiotensin II antagonists |
CA1338238C (fr) * | 1988-01-07 | 1996-04-09 | David John Carini | Imidazoles bloquant les recepteurs de l'angiotensine ii et combinaisons de ces imidazoles avec des diuretiques et des anti-inflammatoires non steroidiens |
US4916129A (en) | 1989-01-19 | 1990-04-10 | E. I. Du Pont De Nemours And Company | Combination β-blocking/angiotensin II blocking antihypertensives |
EP0400835A1 (fr) | 1989-05-15 | 1990-12-05 | Merck & Co. Inc. | Benzimidazoles substitués comme antagoniste d'angiotensine II |
IE64514B1 (en) | 1989-05-23 | 1995-08-09 | Zeneca Ltd | Azaindenes |
GB8911854D0 (en) | 1989-05-23 | 1989-07-12 | Ici Plc | Heterocyclic compounds |
US5064825A (en) * | 1989-06-01 | 1991-11-12 | Merck & Co., Inc. | Angiotensin ii antagonists |
WO1991012002A1 (fr) * | 1990-02-13 | 1991-08-22 | Merck & Co., Inc. | Agents antagonistes de l'angiotensine ii a base d'imidazoles dans lesquels est incorpore un element de benzyle substitue |
US5140037A (en) * | 1990-03-20 | 1992-08-18 | E. I. Du Pont De Nemours And Company | Treatment of central nervous system disorders with imidazole angiotensin-ii receptor antagonists |
-
1992
- 1992-02-20 IS IS3819A patent/IS1756B/is unknown
- 1992-02-20 CA CA002229000A patent/CA2229000C/fr not_active Expired - Lifetime
- 1992-02-20 FI FI920749A patent/FI112942B3/fi not_active IP Right Cessation
- 1992-02-20 CA CA002061607A patent/CA2061607C/fr not_active Expired - Lifetime
- 1992-02-20 IE IE054092A patent/IE920540A1/en active Protection Beyond IP Right Term
- 1992-02-21 DK DK92301449T patent/DK0503785T3/da active
- 1992-02-21 ES ES92301449T patent/ES2157895T7/es active Active
- 1992-02-21 PT PT92301449T patent/PT503785E/pt unknown
- 1992-02-21 ES ES93200195T patent/ES2156866T3/es not_active Expired - Lifetime
- 1992-02-21 KR KR1019920002676A patent/KR0128289B1/ko not_active IP Right Cessation
- 1992-02-21 DE DE200512000051 patent/DE122005000051I1/de active Pending
- 1992-02-21 NO NO19920688A patent/NO304516B3/no not_active IP Right Cessation
- 1992-02-21 IL IL114996A patent/IL114996A/xx not_active IP Right Cessation
- 1992-02-21 DE DE69231798T patent/DE69231798T3/de not_active Expired - Lifetime
- 1992-02-21 DE DE2002199043 patent/DE10299043I2/de active Active
- 1992-02-21 JP JP4034970A patent/JPH07121918B2/ja not_active Expired - Lifetime
- 1992-02-21 DE DE122009000024C patent/DE122009000024I1/de active Pending
- 1992-02-21 CZ CS1992516A patent/CZ289194B6/cs not_active IP Right Cessation
- 1992-02-21 EP EP92301449A patent/EP0503785B3/fr not_active Expired - Lifetime
- 1992-02-21 EP EP93200195A patent/EP0545912B1/fr not_active Expired - Lifetime
- 1992-02-21 NZ NZ241681A patent/NZ241681A/en not_active IP Right Cessation
- 1992-02-21 AT AT92301449T patent/ATE200777T1/de active
- 1992-02-21 DE DE69231801T patent/DE69231801T2/de not_active Expired - Lifetime
- 1992-02-21 HU HU9200578A patent/HU223338B1/hu active Protection Beyond IP Right Term
- 1992-02-21 DK DK93200195T patent/DK0545912T3/da active
- 1992-02-21 RU RU95101430A patent/RU2128173C1/ru active
- 1992-02-21 IL IL10103492A patent/IL101034A/en not_active IP Right Cessation
- 1992-02-21 PT PT93200195T patent/PT545912E/pt unknown
- 1992-02-21 CN CN92102075A patent/CN1045770C/zh not_active Expired - Lifetime
- 1992-02-21 AT AT93200195T patent/ATE200778T1/de active
- 1992-02-21 DE DE122011000011C patent/DE122011000011I1/de active Pending
-
1994
- 1994-10-28 HU HU9601179A patent/HU223667B1/hu active IP Right Grant
-
1995
- 1995-06-29 HU HU95P/P00605P patent/HU211934A9/hu unknown
- 1995-08-18 IL IL11499695A patent/IL114996A0/xx unknown
- 1995-11-02 FI FI955248A patent/FI112941B/fi not_active IP Right Cessation
- 1995-11-09 NO NO954507A patent/NO304517B1/no not_active IP Right Cessation
-
1997
- 1997-12-24 CN CN97123452A patent/CN1101384C/zh not_active Expired - Lifetime
- 1997-12-24 CN CN97126347A patent/CN1121859C/zh not_active Expired - Lifetime
-
1998
- 1998-11-26 HK HK98112355A patent/HK1011361A1/xx not_active IP Right Cessation
- 1998-12-09 HK HK98113006A patent/HK1011969A1/xx not_active IP Right Cessation
-
2001
- 2001-05-22 GR GR20010400760T patent/GR3035906T3/el unknown
- 2001-05-22 GR GR20010400763T patent/GR3035909T3/el unknown
-
2003
- 2003-08-01 NL NL300133C patent/NL300133I2/nl unknown
- 2003-11-27 NO NO2003009C patent/NO2003009I2/no unknown
-
2004
- 2004-01-26 LU LU91056C patent/LU91056I2/fr unknown
-
2006
- 2006-03-30 NL NL300227C patent/NL300227I1/nl unknown
- 2006-10-09 NO NO2006012C patent/NO2006012I1/no unknown
-
2007
- 2007-04-02 LU LU91330C patent/LU91330I2/fr unknown
-
2009
- 2009-02-13 NL NL300375C patent/NL300375I1/nl unknown
- 2009-05-11 LU LU91571C patent/LU91571I2/fr unknown
- 2009-09-11 NO NO2009019C patent/NO2009019I1/no unknown
-
2011
- 2011-07-26 LU LU91847C patent/LU91847I2/fr unknown
- 2011-08-10 NO NO2011013C patent/NO2011013I1/no unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
LU91056I2 (fr) | Dérivés de 1-biphénylimidazole, leur préparation et leur utilisation thérapeutique. |